首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >LPS pretreatment ameliorates D-galactosamine/lipopolysaccharide-induced acute liver failure in rat
【2h】

LPS pretreatment ameliorates D-galactosamine/lipopolysaccharide-induced acute liver failure in rat

机译:LPS预处理可改善D-半乳糖胺/脂多糖诱导的大鼠急性肝衰竭

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute liver failure (ALF) remains an extremely poor prognosis and high mortality; with no effective treatments. The endotoxin tolerance (ET) phenotype has been reported to exhibit protective activities in several sepsis models. We now investigated the effects and underlying intraperitoneal injection of the same volume of pyrogen-free 0.9% sodium chloride instead of LPS for five consecutive days before D-GalN/LPS injection in rats. The serum levels of TNF-α, IL-6, ALT, AST and TBiL from ET + ALF group and ALF group were measured at different time points. Our results showed that ET + ALF group markedly reduced the serum levels of TNF-α, IL-6, ALT, AST and TBiL and histological features in the ET + ALF group were improved significantly. Furthermore, LPS pre-treatment inhibited D-GalN/LPS-induced NF-κB activation, Bax activation, signal transducer and activator of transcription-1 (STAT1) and signal transducer and activator of transcription-3 (STAT3) activities. LPS pre-treatment also significantly enhance the expression of suppressors of cytokine signaling 1 (SOCS1) and suppressors of cytokine signaling 3 (SOCS3). Our experimental data indicated that ET might alleviate D-GalN/LPS-induced ALF by inhibiting the inflammatory response, inactivation of STAT1 and STAT3 and up-regulation of SOCS1 and SOCS3.
机译:急性肝衰竭(ALF)预后极差,死亡率高。没有有效的治疗方法。据报道,内毒素耐受(ET)表型在几种败血症模型中表现出保护活性。现在,我们在连续D天连续五天研究了相同体积的无热原的0.9%氯化钠而不是LPS的腹膜内注射的作用,并在大鼠D-GalN / LPS注射之前进行了腹腔内注射。在不同的时间点分别测量了ET + ALF组和ALF组的血清TNF-α,IL-6,ALT,AST和TBiL的水平。我们的结果表明,ET + ALF组可显着降低血清TNF-α,IL-6,ALT,AST和TBiL的水平,并且ET + ALF组的组织学特征得到明显改善。此外,LPS预处理抑制了D-GalN / LPS诱导的NF-κB活化,Bax活化,信号转导和转录激活因子1(STAT1)和信号转导和转录激活因子3(STAT3)的活性。 LPS预处理还可以显着增强细胞因子信号传导抑制剂1(SOCS1)和细胞因子信号传导抑制剂3(SOCS3)的表达。我们的实验数据表明,ET可能通过抑制炎症反应,STAT1和STAT3的失活以及SOCS1和SOCS3的上调来减轻D-GalN / LPS诱导的ALF。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号